FDA signals are starting to break down, and biotech is feeling it. One company is collapsing while another is breaking through.

As lawmakers return to Washington for a packed schedule of healthcare hearings, the conversation will be shaped by what’s happening inside the biotech ecosystem right now, both the breakthroughs and the breakdowns.

In this episode of Making Medicine, we connect the dots between what’s unfolding on Capitol Hill and what companies are experiencing on the ground.

We start with the policy backdrop: multiple hearings across the House and Senate, including appearances by HHS Secretary RFK Jr. and a renewed focus on drug pricing, FDA oversight, and the future of biomedical innovation.

Then we turn to two stories that highlight what’s at stake.

On one side is Replimune, a biotech facing layoffs and a collapsing market response after repeated FDA rejections and what leadership described as inconsistent communication and a slow-moving regulatory process.

On the other is Revolution Medicines, whose pancreatic cancer drug is delivering unprecedented clinical results and offering real hope to patients, a powerful example of what the innovation ecosystem looks like when it works.

Together, these stories raise a critical question: Can companies and investors still rely on FDA signals?

Because when those signals become unpredictable, capital pulls back, risk tolerance shrinks, and fewer breakthrough therapies get funded.

We also explore how early-stage investors rely on regulatory clarity, how large pharma acquisitions are helping fuel the biotech ecosystem, and why Congress plays a critical role in shaping what comes next.

The takeaway is simple: Biotech doesn’t succeed or fail in isolation. Policy, regulation, and capital all move together.

Join the Conversation ⬇️
Are we creating a system that rewards safe, incremental drugs over true breakthroughs? If FDA decisions feel unpredictable, does capital move elsewhere, or does innovation slow down entirely?
Drop your thoughts in the comments below 👇

If you're new to the Making Medicine Podcast, we're happy you're here! Follow us for more:  https://x.com/MakingMedPod
https://www.instagram.com/makingmedicinepod/
https://www.linkedin.com/showcase/making-medicine-podcast/about/?viewAsMember=true

Time Stamps
00:00 Intro + Why Biotech Policy Matters Right Now
00:38 Congress Returns: RFK Jr., Drug Pricing, and Key Hearings
03:29 When FDA Delays Kill Companies (Kezar Case)
04:01 Replimune Collapse: From Breakthrough to Rejection
05:46 The Real Risk: Can Investors Trust FDA Signals?
06:51 Revolution Medicines: A Cancer Breakthrough
07:49 Historic Results: First Survival Gains in Pancreatic Cancer
08:22 How Biotech Actually Works (Startups → Pharma)
09:56 Why Big Pharma Deals Matter for Patients
10:06 Collapse vs Breakthrough: Which Future Are We Heading Toward?
10:22 What Congress and FDA Need to Fix
10:50 Faster Drug Development? New FDA Pathway Explained
12:25 Final Take: The Stakes for U.S. Biotech Leadership

DISCLAIMER: We’re reporting on the headlines, not making medical recommendations. For personal health questions, always consult a doctor.

#Biotech #FDA #DrugDevelopment #HealthcarePolicy #BiotechInvesting